Vuity (vutrisiran) – generic status
| Topic | What you need to know |
|-------|-----------------------|
| Brand vs. generic name | Vuity is the brand name. The drug’s generic (chemical) name is vutrisiran. If a generic ever comes to market, it will be sold under that name (e.g., “vutrisiran 150 µg/mL, subcutaneous”). |
| Current availability | As of now—late 2026—there is no generic version available in the U.S. or other markets. Vuity remains a brand‑only product. |
| Why no generic yet? | 1. Patents & exclusivity – Vuity is protected by a suite of patents that cover the active drug, formulation, and delivery system, with exclusivity likely lasting at least until the early‑to‑mid‑2030s. 2. Complex molecule – Vutrisiran is a small‑interfering RNA (siRNA) therapy, a biologic (not a conventional small‑molecule drug). Generics for biologics require a “biosimilar” pathway, which is more stringent and takes longer than for typical generics. 3. Regulatory pathway – A generic (or biosimilar) applicant would need to submit a 505(b)(2) or biosimilar application to the FDA, demonstrating bioequivalence and clinical equivalence, which can take several years. |
| Projected timeline | If a generic applicant starts the process now, the earliest a biosimilar could be approved would be mid‑2030s, assuming no patent challenges and a smooth regulatory review. |
| Alternative treatment options | While waiting for a generic, patients can consider other approved ATTR‑neuropathy therapies:
• Tafamidis (Vyndaqel/Vyndamax) – TTR stabilizer.
• Patisiran (Onpattro) – siRNA that lowers TTR (approved for both cardiomyopathy and neuropathy).
• Inotersen (Tegsedi) – antisense oligonucleotide.
• Other investigational agents – several in late‑phase trials. |
| Cost & affordability | Vuity’s list price is high (~$30,000–$35,000 per year), and insurance coverage varies.
Patient assistance programs are available:
• Sanofi’s Vutrisiran Patient Assistance program.
• Pharmacy benefit manager (PBM) “preferred formulary” options.
• Specialty pharmacy assistance for prior authorization. |
| Practical next steps for patients | 1. Check insurance – confirm coverage, prior‑authorization requirements, and out‑of‑pocket costs. 2. Ask your prescriber – they can help navigate assistance programs and verify the latest formulary status. 3. Ask the pharmacy – they may know of any “equivalent” preparations or manufacturer discounts. 4. Stay informed – monitor FDA announcements; a generic filing would be publicly announced. |
| Key takeaway | Vuity (vutrisiran) has no generic in the marketplace as of now. It is a brand‑only siRNA drug, and a generic (biosimilar) is unlikely to appear until the early‑to‑mid‑2030s, pending patent expirations and regulatory approvals. Patients and providers should therefore focus on current coverage options and alternative ATTR‑neuropathy therapies while awaiting any future generic entry. |
---
Quick FAQ
| Q | A |
|---|---|
| Does the drug have a generic name I can ask for? | The drug’s generic name is vutrisiran, but no generic product is available yet. |
| Will a generic ever be approved? | Potentially in the 2030s, but it depends on patent expiry, a biosimilar filing, and FDA approval. |
| Can I get a lower‑priced version today? | No generic, but you can explore manufacturer assistance, insurance coverage, or alternative ATTR therapies. |
Feel free to let me know if you’d like more detail on insurance navigation, alternative drugs, or how to apply for the patient assistance program.